Top Story

Indivior submits NDA to market RBP-7000 for schizophrenia

Indivior submits NDA to market RBP-7000 for schizophrenia
October 13, 2017

Indivior recently submitted a New Drug Application to the FDA for marketing approval of RBP-7000, a once-monthly injectable risperidone in the Atrigel delivery system, for schizophrenia, according to a manufacturer-issued press release.

The submission included results from a phase 3 trial and an open-label, long-term safety study of RBP-7000.

In the Journals

Study finds substantial genetic risk for schizophrenia

October 12, 2017
Analysis of nationwide twin data from Denmark estimated heritability of schizophrenia at 79%, indicating a significant genetic risk. “The new estimate of…
In the Journals

Study reveals potential drug target for bipolar disorder, schizophrenia

October 11, 2017
Recent findings suggested dopamine synthesis capacity as a potential drug target for bipolar disorder and schizophrenia. “The dopamine hypothesis suggests that…
In the Journals

Study shows long-term efficacy of Aristada for schizophrenia

October 10, 2017
Efficacy of Aristada continued for 1 year among individuals successfully treated for an acute episode of schizophrenia, according to recent findings. “Studies…
More Headlines »

Risperidone Use in Children: Gynecomastia, Hyperprolactinemia, and Other Controversies

Psychiatric Annals, April 2015, Volume 45 Issue 4
The use of neuroleptics, especially risperidone, and their common side effect of hyperprolactinemia and the rare but…
More »

First-Episode Psychosis: November 2015

Keck School of Medicine of USC and Psychiatric Annals

Psychosis occurs first in young people and then can progress into a chronic lifelong disorder. Although some patients…
More »
Resource Centers
Psych Congress

Psych Congress

Meeting News Coverage

VIDEO: Recently approved Nuplazid fills treatment gap in Parkinson’s disease

May 25, 2016
More »